April 02, 2013
Consumers in Pennsylvania and Florida hit Shire US Inc. with a pair of putative class actions this week accusing the pharmaceutical company of illegally stifling competition for Adderall XR, its blockbuster treatment for attention deficit hyperactivity disorder, with patent settlements and supply agreements with generic rivals.
March 06, 2013
A New York federal judge on Wednesday tossed a drug wholesaler's putative antitrust class action against Shire LLC for allegedly stifling generic competition for its blockbuster ADHD treatment Adderall XR, saying the company's behavior within its patent licensing agreements didn't create an antitrust issue.